Pharmaceutical manufacturers face a variety of complex challenges in managing the supply chain for GLP-1 drugs, primarily used to treat diabetes and obesity.

As demand for these sensitive medications surges, the industry is focusing on the expansion of production capacity, safeguarding product quality, and maintaining logistics and distribution security. Cold chain solutions, such as advanced temperature monitoring, thermo-isolating packaging, and real-time tracking, are essential to preserving drug integrity.

In this article, Dan Bell, Marken’s Senior Vice President of Innovation & Strategic Operations, explores the increased pressure on the supply chain driven by the rising popularity of GLP-1 drugs. He discusses how Marken is positioned to streamline the supply chain and mitigate costs through route forecasting, stringent quality control, risk mitigation, and cross-collaboration among all stakeholders, ensuring these life-saving drugs remain accessible to patients.